rDNA: profile and news
Pfizer's Genotropin (Somatropin [rDNA origin] for Injection) ... May 4, 2006
...announced today that the US Food and Drug Administration (FDA) has approved a supplemental new drug application for Genotropin® (somatropin [rDNA origin] for ... - DG News
New technology speeds up bird flu production May 5, 2006
Recombinant DNA (rDNA) vaccine technology could be the answer as it represents a powerful tool for an innovative vaccine design process known as "genetic ... - In-PharmaTechnologist.com,
Tercica Presents Updated Increlex Long-Term Treatment Data at the ... May 11, 2006
...(Nasdaq:TRCA) presented today updated safety and efficacy data from 321 patient-years of treatment with Increlex(TM) (mecasermin (rDNA origin) injection) from ... - Genetic Engineering News,
Phase III Trial of Oral Cladribine, a Novel Investigational ... May 4, 2006
Luveris(R) (lutropin alfa), Ovidrel PreFilled Syringe(R)/Ovitrelle(R) (choriogonadotropin alfa injection), Serostim(R) [somatropin (rDNA origin) for injection ... - PR Newswire (press release),
Lilly to Extend Patient Assistance Programs for Medicare Patients May 10, 2006
A favorable opinion from the OIG would allow Lilly to continue providing Forteo(R) (teriparatide [rDNA origin] injection), a treatment for osteoporosis, and ... - PR Newswire (press release),
Reader's Digest Association Announces 3Q Fiscal 2006 Earnings ... Apr 26, 2006
RD North America (RDNA) increased 4 percent to $220 million. ... RDNA profit increased 10 percent to $24 million. RDI profit was $5 million, versus $7 million. ... - PR Newswire (press release),
Lilly to extend patient assistance programs for Medicare patients May 11, 2006
A favorable opinion from the OIG would allow Lilly to continue providing Forteo (teriparatide [rDNA origin] injection), a treatment for osteoporosis, and ... - News-Medical.net,
Tercica Reports First Quarter Financial Results; Conference Call ... May 9, 2006
...revenue for the first quarter ended March 31, 2006 was $85,000, reflecting the initial quarter of sales of Increlex(TM) (mecasermin (rDNA origin) injection). ... - Genetic Engineering News,
Tercica Announces Poster Presentation at Pediatric Endocrinology ... May 8, 2006
...today that it will be presenting updated safety and efficacy data from 321 patient-years of treatment with Increlex(TM) (mecasermin (rDNA origin) injection ... - Genetic Engineering News,
"Junk" RNA regulates important cellular processes May 9, 2006
...previously regarded as "junk" without special function are able to remodel the chromatin structure and, thus, to switch off the gene activity of the rDNA locus ... - News-Medical.net,
OutSystems Platform Supports Fast Roll-Out of US Biotech May 9, 2006
The company's first product, Increlex(TM) (mecasermin -rDNA origin- injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the ... - The Open Press (press release)
NPS Pharmaceuticals Reports First Quarter 2006 Operating Results May 2, 2006
Recent developments included: * The European Commission approved Preotact(R) (parathyroid hormone [rDNA origin] for injection) for the treatment of ... - MSN Money
Tercica to Present at Baird's 27th Annual Growth Stock Conference ... May 4, 2006
The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the ... - Genetic Engineering News,
Tercica Announces Two Presentations at the Pediatric Academic ... Apr 20, 2006
...highlight two newly developed assays for use in clinical studies to monitor children who have been treated with Increlex(TM) (mecasermin (rDNA origin) injection ... - Genetic Engineering News,
IPLEX(TM) Demonstrates Significant, Dose-Dependent Increases in ... May 1, 2006
News) today announced results from a prospective, multicenter clinical trial of rhIGF-I/rhIGFBP-3, or IPLEX(TM) (mecasermin rinfabate [rDNA origin] injection ... - Yahoo! News (press release)
Lilly Reports Q1 EPS of $.77, or 13% Growth Apr 20, 2006
...injection of recombinant DNA origin, Lilly) Humalog(R) Mix 50/50(TM) (50% insulin lispro protamine suspension, 50% insulin lispro injection (rDNA origin, Lilly ... - MSN Money
NORD Honors Insmed for Role in Developing Treatments for Rare ... Apr 25, 2006
Organization for Rare Disorders (NORD) last night at its annual Tribute Banquet for the development of IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection ... - International News Service,
European Commission Issues Marketing Authorization for Preotact ... Apr 26, 2006
...and its partner Nycomed announced today that the European Commission has granted marketing authorization for Preotact (parathyroid hormone [rDNA origin] for ... - DG News
European Commission Issues Marketing Authorization for Preotact(R) ... Apr 26, 2006
Nycomed (www.nycomed.com) announced today that the European Commission has granted marketing authorization for Preotact (parathyroid hormone [rDNA origin] for ... - Yahoo! News (press release)
